MY199104A - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents
Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorderInfo
- Publication number
- MY199104A MY199104A MYPI2019003348A MYPI2019003348A MY199104A MY 199104 A MY199104 A MY 199104A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY 199104 A MY199104 A MY 199104A
- Authority
- MY
- Malaysia
- Prior art keywords
- bipolar disorder
- alleviation
- prevention
- treatment
- carbamate compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY199104A true MY199104A (en) | 2023-10-13 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019003348A MY199104A (en) | 2016-12-14 | 2017-12-14 | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (OSRAM) |
| EP (1) | EP3556366B1 (OSRAM) |
| JP (1) | JP7208139B2 (OSRAM) |
| KR (1) | KR102635938B1 (OSRAM) |
| CN (1) | CN110290788A (OSRAM) |
| AU (1) | AU2017374458B2 (OSRAM) |
| BR (1) | BR112019011930A2 (OSRAM) |
| CL (1) | CL2019001618A1 (OSRAM) |
| IL (1) | IL267195B2 (OSRAM) |
| MX (1) | MX2019006940A (OSRAM) |
| MY (1) | MY199104A (OSRAM) |
| WO (1) | WO2018111008A1 (OSRAM) |
| ZA (1) | ZA201903747B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854391B1 (en) * | 2018-09-21 | 2024-03-13 | SK Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| WO2020060252A1 (ko) * | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| AU2020389425A1 (en) * | 2019-11-22 | 2022-06-02 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU6100A (sh) * | 1997-08-14 | 2002-10-18 | F.Hoffmann-La Roche Ag. | Heterociklični viniletri protiv neuroloških poremećaja |
| CZ2004266A3 (cs) * | 2000-07-21 | 2005-02-16 | Teva Pharmaceutical Industries, Ltd. | Použití derivátů amidů kyseliny valproové a kyseliny 2-valproenové pro léčbu mánie při bipolární poruše |
| ATE324108T1 (de) * | 2001-02-27 | 2006-05-15 | Ortho Mcneil Pharm Inc | Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung |
| US7122576B2 (en) * | 2001-02-27 | 2006-10-17 | Plata-Salaman Carlos R | Carbamate compounds for use in preventing or treating bipolar disorder |
| EA200701065A1 (ru) | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US20080103199A1 (en) * | 2006-10-31 | 2008-05-01 | Haas Magali | Treatment of pervasive developmental disorders |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) * | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9981950B2 (en) | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
-
2017
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt unknown
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190314337A1 (en) | 2019-10-17 |
| IL267195B1 (en) | 2024-01-01 |
| AU2017374458B2 (en) | 2023-03-02 |
| CA3046297A1 (en) | 2018-06-21 |
| CL2019001618A1 (es) | 2019-08-23 |
| CN110290788A (zh) | 2019-09-27 |
| EP3556366B1 (en) | 2025-10-22 |
| ZA201903747B (en) | 2021-01-27 |
| KR20190087572A (ko) | 2019-07-24 |
| IL267195A (OSRAM) | 2019-07-31 |
| EP3556366A4 (en) | 2020-06-17 |
| IL267195B2 (en) | 2024-05-01 |
| EP3556366A1 (en) | 2019-10-23 |
| RU2019121913A (ru) | 2021-01-15 |
| RU2019121913A3 (OSRAM) | 2021-04-21 |
| BR112019011930A2 (pt) | 2019-10-29 |
| US11571410B2 (en) | 2023-02-07 |
| MX2019006940A (es) | 2019-09-06 |
| AU2017374458A1 (en) | 2019-07-04 |
| JP2020502106A (ja) | 2020-01-23 |
| WO2018111008A1 (ko) | 2018-06-21 |
| KR102635938B1 (ko) | 2024-02-13 |
| JP7208139B2 (ja) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| MY199104A (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| MX2017013281A (es) | Metodos para tratar transtornos del almacenamiento lisosomal. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| SG11201803867TA (en) | Sodium channel blocker | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus | |
| MY198417A (en) | Use of Carbamate Compound for Preventing, Alleviating, or Treating Tremors or Tremor Syndrome | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. |